Top
image credit: Adobe Stock

New Competitor to Wegovy, Retatrutide, Shows Promise in Clinical Trials

June 27, 2023

Via: Drugs.com

An experimental drug appears to outperform the trendy medications Wegovy and Ozempic for both weight loss and diabetes control, a pair of early clinical trials shows.

Retatrutide helped people with obesity drop about one-quarter of their starting weight, on average, during 48 weeks taking the drug, according to phase 2 trial results published online June 26 in the New England Journal of Medicine.

“What is clear is that 24% weight loss from a single drug has not been seen before,” said co-researcher Dr. Lee Kaplan, an associate professor with Harvard Medical School. “And the subjects in the trial were still losing weight at the end.”

Read More on Drugs.com